NeoGenomics Inc. (NEO)
NeoGenomics Inc. (NEO) Stock Price, Analysis & Data
| Bid | 11.94 |
| Market Cap | 2.1B |
| Revenue (ttm) | 766.29M |
| Net Income (ttm) | -51.88M |
| Beta | 1.73 |
| EPS (ttm) | -0.39 |
| PE Ratio (ttm) | n/a |
| Forward PE | 48.35 |
| P/B (ttm) | 2.66 |
| P/S (ttm) | 2.78 |
| Earnings Date | Apr 29, 2025 |
| Ask | 20.82 |
| Volume | 601,701 |
| Avg. Volume (20D) | 2,784,254 |
| Open | 16.40 |
| Previous Close | 16.53 |
| Day's Range | 16.24 - 16.58 |
| 52-Week Range | 5.94 - 16.92 |
| Analyst | Buy |
| Price Target | 19 (16.21%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing se...
Financial Performance
In 2025, NeoGenomics's revenue was 727.33M, an increase of 10.11% compared to the previous year's 660.57M. Earnings were -108.03M, an increase of 37.22%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for NEO stock is "Buy". The 12-month stock price forecast is 19, which is upside of 16.21% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
